Laura Oliphant, Aehr Test Systems director, sells $399k in shares

Aehr Test Systems saw mixed operating results but strong demand signals, including a record $41 million production order from a hyperscale customer for package-level burn-in of custom AI processors. Q3 2026 EPS came in at -$0.05, better than the -$0.07 forecast, while revenue missed at $10.3 million versus $10.8 million expected. Separately, Director Laura Oliphant sold 4,665 shares at $85.5879 for $399,267, and analysts raised price targets to $61 and $56 on improving bookings momentum.

Analysis

AEHR is increasingly behaving like a classic “bookings-led multiple” story rather than a clean earnings story: the market is willing to pay for hyperscale AI exposure today because the order flow appears to be validating a multi-quarter rollout, but that premium is fragile if conversion slips. The second-order issue is that package-level burn-in for custom ASICs is still an early-node infrastructure spend; that means the addressable upside can compound, but it also makes revenue recognition lumpy and highly dependent on one or two platform customers. In practice, the stock will likely trade on backlog quality and delivery cadence more than on near-term EPS prints.

The insider sale is not automatically bearish, but it matters because it occurred after an extreme rerating and at a time when the company is still posting negative earnings. That combination often marks the point where bullish consensus becomes self-reinforcing: analysts extrapolate bookings into a straight-line revenue ramp, while the market underprices the risk that a handful of orders get pushed out by a quarter or two. The main losers if this enthusiasm fades are late momentum holders; the main beneficiaries are adjacent equipment vendors and socket/module suppliers that can piggyback on the same AI capex cycle without carrying the same customer concentration risk.

The contrarian view is that the stock may already be discounting a very large portion of the 2027 growth story. If the hyperscale customer’s deployment schedule normalizes or the AI ASIC program changes specs, AEHR could de-rate quickly because the current valuation assumes scarcity value and durable share gains, not just one large order. Over the next 1-3 months, the key catalyst is whether management can translate bookings into visible revenue acceleration; over 6-12 months, the real test is gross margin stability as mix shifts from systems to consumables and support.

Key Decisions for Investors

• Avoid initiating fresh outright longs in AEHR at current levels; wait for a pullback or a post-earnings setup where the market can verify conversion of backlog into revenue, because the stock is still pricing a lot of 2027 optimism.
• For existing longs, consider a partial hedge via short-dated call overwrites or put spreads into the next earnings window; the asymmetry is better for protecting gains than chasing incremental upside after an 891% run.
• Pair trade idea: long a diversified AI infrastructure equipment name with recurring revenue exposure and short AEHR into strength, betting that the market will eventually reward lower customer-concentration and higher revenue visibility.
• If you want exposure to the AI hardware supply chain, prefer a basket of adjacent names over a single-name AEHR bet; the risk/reward is superior because one customer delay should not dominate outcomes.
• Use a tactical trigger: if AEHR sustains above the current price while backlog converts into sequential revenue growth for 2 consecutive quarters, reassess for a momentum continuation trade; absent that, treat rallies as sellable.